Back to Search
Start Over
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia
- Source :
- American Journal of Hematology. 91:800-805
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
-
Abstract
- Tumor hypoxia causes resistance to radiation and chemotherapy. Evofosfamide (TH-302) has exhibited specific hypoxia-dependent cytotoxicity against primary acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) samples in vitro. Based on these findings, a Phase I study of evofosfamide was designed for patients with relapsed/refractory leukemia (NCT01149915). In this open-label study, patients were treated with evofosfamide as a 30-60 min/day infusion on Days 1-5 of a 21-day cycle (Arm A, n = 38) or as a continuous infusion over 120 hr over Days 1-5 of a 21-day cycle (Arm B, n = 11). Forty-nine patients were treated including 39 (80%) with AML and 9 (18%) with ALL. Patients had received a median of five prior therapies. In Arm A, the dose-limiting toxicities (DLTs) were grade 3 esophagitis, observed at a dose of 550 mg/m(2) . The maximum tolerated dose (MTD) was a daily dose of 460 mg/m(2) . In Arm B, the DLTs were grade 3 stomatitis and hyperbilirubinemia, observed at a daily dose of 460 mg/m(2) . The continuous infusion MTD was a daily dose of 330 mg/m(2) . Hypoxia markers HIF-1α and CAIX were highly expressed in leukemic bone marrow and were significantly reduced after evofosfamide therapy. The combined overall response rate in Arms A and B was 6% (2 CR/CRi and 1 PR), with all responses seen in Arm A. Evofosfamide has shown limited activity in heavily pretreated leukemia patients. Further evaluation investigating evofosfamide in combination with cytotoxic or demethylating agents is warranted. Am. J. Hematol. 91:800-805, 2016. © 2016 Wiley Periodicals, Inc.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Myeloid
medicine.medical_treatment
Salvage therapy
Pharmacology
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Stomatitis
Chemotherapy
Evofosfamide
business.industry
Myeloid leukemia
Hematology
medicine.disease
Leukemia
030104 developmental biology
medicine.anatomical_structure
chemistry
030220 oncology & carcinogenesis
Bone marrow
business
Subjects
Details
- ISSN :
- 03618609
- Volume :
- 91
- Database :
- OpenAIRE
- Journal :
- American Journal of Hematology
- Accession number :
- edsair.doi...........dce08ee8eef8196f2014eb592f5ed617